Top

Published in:

01-01-2013 | Review

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Authors: S. Kralisch, M. Fasshauer

Published in: Diabetologia | Issue 1/2013

Abstract

Adipocyte fatty acid binding protein (AFABP, also known as aP2 and FABP4) has recently been introduced as a novel fat-derived circulating protein. AFABP serum concentrations are positively correlated with markers of the metabolic syndrome and vascular disease in various cross-sectional and interventional studies. Furthermore, a small set of prospective studies indicates that high AFABP serum levels at baseline predict the risk for metabolic and vascular morbidity and mortality. Studies in Afabp (also known as Fabp4) knockout mice and AFABP inhibitor-treated animals suggest that total AFABP promotes insulin resistance, hypertriacylglycerolaemia and atherosclerosis by ligand/ligand delivery, as well as ligand-independent mechanisms. In contrast, the pathophysiological significance of circulating AFABP and the mechanisms leading to its release remain to be established. The current review summarises recent findings on the regulation and potential role of AFABP in metabolic and vascular disease.

Ahima RS, Flier JS (2000) Leptin. Annu Rev Physiol 62:413–437PubMedCrossRef

Fruebis J, Tsao TS, Javorschi S et al (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMedCrossRef

Baxa CA, Sha RS, Buelt MK et al (1989) Human adipocyte lipid-binding protein—purification of the protein and cloning of its complementary-DNA. Biochemistry 28:8683–8690PubMedCrossRef

Fu YC, Luo NL, Lopes-Virella MF, Garvey WT (2002) The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 165:259–269PubMedCrossRef

Elmasri H, Karaaslan C, Teper Y et al (2009) Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 23:3865–3873PubMedCrossRef

Bernlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly TJ (1984) Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci USA 81:5468–5472PubMedCrossRef

Bernlohr DA, Bolanowski MA, Kelly TJ, Lane MD (1985) Evidence for an increase in transcription of specific mRNAs during differentiation of 3t3-l1 preadipocytes. J Biol Chem 260:5563–5567PubMed

Bernlohr DA, Doering TL, Kelly TJ, Lane MD (1985) Tissue specific expression of p422 protein, a putative lipid carrier, in mouse adipocytes. Biochem Biophys Res Commun 132:850–855PubMedCrossRef

Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS (1988) Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 263:9402–9408PubMed

10.

Yang VW, Christy RJ, Cook JS, Kelly TJ, Lane MD (1989) Mechanism of regulation of the 422(Ap2) gene by CAMP during preadipocyte differentiation. Proc Natl Acad Sci USA 86:3629–3633PubMedCrossRef

11.

Christy RJ, Yang VW, Ntambi JM et al (1989) Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev 3:1323–1335PubMedCrossRef

12.

Cabré A, Lázaro I, Girona J et al (2007) Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 195:e150–e158PubMedCrossRef

13.

Kletzien RF, Foellmi LA, Harris PKW, Wyse BM, Clarke SD (1992) Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol 42:558–562PubMed

14.

Fisher RM, Eriksson P, Hoffstedt J et al (2001) Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia 44:1268–1273PubMedCrossRef

15.

Coe NR, Bernlohr DA (1998) Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1391:287–306PubMedCrossRef

16.

Lalonde JM, Bernlohr DA, Banaszak LJ (1994) X-ray crystallographic structures of adipocyte lipid-binding protein complexed with palmitate and hexadecanesulfonic acid—properties of cavity binding-sites. Biochemistry 33:4885–4895PubMedCrossRef

17.

Xu ZH, Bernlohr DA, Banaszak LJ (1993) The adipocyte lipid-binding protein at 1.6-a resolution—crystal-structures of the apoprotein and with bound saturated and unsaturated fatty-acids. J Biol Chem 268:7874–7884PubMed

18.

Liou HL, Storch J (2001) Role of surface lysine residues of adipocyte fatty acid-binding protein in fatty acid transfer to phospholipid vesicles. Biochemistry 40:6475–6485PubMedCrossRef

19.

Shen WJ, Liang Y, Hong R et al (2001) Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase. J Biol Chem 276:49443–49448PubMedCrossRef

20.

Smith AJ, Thompson BR, Sanders MA, Bernlohr DA (2007) Interaction of the adipocyte fatty acid-binding protein with the hormone-sensitive lipase—regulation by fatty acids and phosphorylation. J Biol Chem 282:32424–32432PubMedCrossRef

21.

Hertzel AV, Hellberg K, Reynolds JM et al (2009) Identification and characterization of a small molecule inhibitor of fatty acid binding proteins. J Med Chem 52:6024–6031PubMedCrossRef

22.

Smith AJ, Sanders MA, Juhlmann BE, Hertzel AV, Bernlohr DA (2008) Mapping of the hormone-sensitive lipase binding site on the adipocyte fatty acid-binding protein (AFABP) identification of the charge quartet on the AFABP/aP2 helix-turn-helix domain. J Biol Chem 283:33536–33543PubMedCrossRef

23.

Adida A, Spener F (2006) Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor γ agonists in cultured cell. Biochim Biophys Acta 1761:172–181PubMedCrossRef

24.

Gillilan RE, Ayers SD, Noy N (2007) Structural basis for activation of fatty acid-binding protein 4. J Mol Biol 372:1246–1260PubMedCrossRef

25.

Ayers SD, Nedrow KL, Gillilan RE, Noy N (2007) Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPAR gamma by FABP4. Biochemistry 46:6744–6752PubMedCrossRef

26.

Tan N-S, Shaw NS, Vinckenbosch N, Liu P, Yasmin R et al (2002) Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 22:5114–5127PubMedCrossRef

27.

Hotamisligil GS, Johnson RS, Distel RJ et al (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274:1377–1379PubMedCrossRef

28.

Coe NR, Simpson MA, Bernlohr DA (1999) Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 40:967–972PubMed

29.

Shaughnessy S, Smith ER, Kodukula S, Storch J, Fried SK (2000) Adipocyte metabolism in adipocyte fatty acid binding protein knockout (aP2(^−/−)) mice after short-term high-fat feeding—functional compensation by the keritinocyte fatty acid binding protein. Diabetes 49:904–911PubMedCrossRef

30.

Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M et al (2005) Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1:107–119PubMedCrossRef

31.

Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS (2000) Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 141:3388–3396PubMedCrossRef

32.

Baar RA, Dingfelder CS, Smith LA et al (2005) Investigation of in vivo fatty acid metabolism in AFABP/aP2(^−/−) mice. Am J Physiol Endocrinol Metab 288:E187–E193PubMedCrossRef

33.

Cao H, Maeda K, Gorgun CZ et al (2006) Regulation of metabolic responses by adipocyte/macrophage fatty acid-binding proteins in leptin-deficient mice. Diabetes 55:1915–1922PubMedCrossRef

34.

Scheja L, Makowski L, Uysal KT et al (1999) Altered insulin secretion associated with reduced lipolytic efficiency in aP2^−/− mice. Diabetes 48:1987–1994PubMedCrossRef

35.

Furuhashi M, Tuncman G, Gorgun CZ et al (2007) Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447:959–965PubMedCrossRef

36.

Lan H, Cheng CC, Kowalski TJ et al (2011) Small-molecule inhibitors of FABP4/5 ameliorate dyslipidaemia but not insulin resistance in mice with diet-induced obesity. J Lipid Res 52:646–656PubMedCrossRef

37.

Yang R, Castriota G, Chen Y et al (2011) RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice. Int J Obes (Lond) 35:217–225CrossRef

38.

Makowski L, Boord JB, Maeda K et al (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7:699–705PubMedCrossRef

39.

Boord JB, Maeda K, Makowski L et al (2002) Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 22:1686–1691PubMedCrossRef

40.

Boord JB, Maeda K, Makowski L et al (2004) Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 110:1492–1498PubMedCrossRef

41.

Lee MYK, Li HY, Xiao Y et al (2011) Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol 162:1564–1576PubMedCrossRef

42.

Tuncman G, Erbay E, Hom X et al (2006) A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 103:6970–6975PubMedCrossRef

43.

Chan KHK, Song YQ, Hsu YH et al (2010) Common genetic variants in fatty acid-binding protein-4 (FABP4) and clinical diabetes risk in the Women’s Health Initiative observational study. Obesity 18:1812–1820PubMedCrossRef

44.

Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS (2005) The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 280:12888–12895PubMedCrossRef

45.

Shum BO, Mackay CR, Gorgun CZ et al (2006) The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J Clin Invest 116:2183–2192PubMedCrossRef

46.

Reynolds JM, Liu Q, Brittingham KC et al (2007) Deficiency of fatty acid-binding proteins in mice confers protection from development of experimental autoimmune encephalomyelitis. J Immunol 179:313–321PubMed

47.

Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR (2005) Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 25:1220–1224PubMedCrossRef

48.

Shi H, Kokoeva MV, Inouye K et al (2006) TLR4 links innate immunity and fatty acid–induced insulin resistance. J Clin Invest 116:3015–3025PubMedCrossRef

49.

Hui X, Li H, Zhou Z et al (2010) Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem 285:10273–10280PubMedCrossRef

50.

Erbay E, Babaev VR, Mayers JR et al (2009) Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 15:1383–1391PubMedCrossRef

51.

Fu YC, Luo LH, Luo NL, Garvey WT (2006) Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis 188:102–111PubMedCrossRef

52.

Wang XQ, Yang K, He YS, Lu L, Shen WF (2011) Receptor mediated elevation in FABP4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in THP-1 Macrophages. Lipids 46:479–486PubMedCrossRef

53.

Saksi J, Nuotio K, Sonninen R et al (2011) Gene expression differences between stroke-associated and asymptomatic carotid plaques. J Mol Med 89:1015–1026PubMedCrossRef

54.

Holm S, Ueland T, Dahl TB et al (2011) Fatty acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PLoS One 6:e28785PubMedCrossRef

55.

Agardh HE, Folkersen L, Ekstrand J et al (2011) Expression of fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosis. J Int Med 269:200–210CrossRef

56.

Peeters W, de Kleijn DPV, Vink A et al (2011) Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J 32:1758–1768PubMedCrossRef

57.

Llaverias G, Noé V, Peñuelas S et al (2004) Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun 318:265–274PubMedCrossRef

58.

Elmasri H, Ghelfi E, Yu C et al (2012) Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis 15:457–468PubMedCrossRef

59.

Xu A, Wang Y, Xu JY et al (2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52:405–413PubMedCrossRef

60.

Veerkamp JH, Maatman RG (1995) Cytoplasmic fatty acid-binding proteins: their structure and genes. Prog Lipid Res 34:17–52PubMedCrossRef

61.

Reese-Wagoner A, Thompson J, Banaszak L (1999) Structural properties of the adipocyte lipid binding protein. Biochim Biophys Acta 1441:106–116PubMedCrossRef

62.

Radisky DC, Stallings-Mann M, Hirai Y, Bissell MJ (2009) Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol 10:228–234PubMedCrossRef

63.

Mohan SK, Rani SG, Yu C (2010) The heterohexameric complex structure, a component in the non-classical pathway for fibroblast growth factor 1 (FGF1) secretion. J Biol Chem 285:15464–15475PubMedCrossRef

64.

Aoki N, Jin-no S, Nakagawa Y et al (2007) Identification and characterization of microvesicles secreted by 3T3-L1 adipocytes: redox- and hormone-dependent induction of milk fat globule-epidermal growth factor 8-associated microvesicles. Endocrinology 148:3850–3862PubMedCrossRef

65.

Lamounier-Zepter V, Look C, Alvarez J et al (2009) Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 105:326–334PubMedCrossRef

66.

Stejskal D, Karpisek M (2006) Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur J Clin Invest 36:621–625PubMedCrossRef

67.

Coll B, Cabre A, Alonso-Villaverde C et al (2008) The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 199:147–153PubMedCrossRef

68.

Cabre A, Lazaro I, Cofan M et al (2010) FABP4 plasma levels are increased in familial combined hyperlipidemia. J Lipid Res 51:1173–1178PubMedCrossRef

69.

Milner KL, van der Poorten D, Xu A et al (2009) Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 49:1926–1934PubMedCrossRef

70.

Yun KE, Kim SM, Choi KM, Park HS (2009) Association between adipocyte fatty acid-binding protein levels and childhood obesity in Korean children. Metabolism 58:798–802PubMedCrossRef

71.

Tonjes A, Kralisch S, Lossner U et al (2012) Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein. Int J Obes 36:766–773CrossRef

72.

Cabre A, Lazaro I, Girona J et al (2008) Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 49:1746–1751PubMedCrossRef

73.

Hsu BG, Chen YC, Lee RP et al (2010) Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J 74:327–331PubMedCrossRef

74.

Yeung DC, Xu A, Cheung CW et al (2007) Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 27:1796–1802PubMedCrossRef

75.

Rhee EJ, Lee WY, Park CY et al (2009) The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 160:165–172PubMedCrossRef

76.

Doi M, Miyoshi T, Hirohata S et al (2011) Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol 10:44

77.

Miyoshi T, Onoue G, Hirohata A et al (2010) Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 211:164–169PubMedCrossRef

78.

Bao YQ, Lu ZG, Zhou M et al (2011) Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in chinese women. PLoS One 6:e19115PubMedCrossRef

79.

Pala L, Monami M, Ciani S et al (2012) Adipokines as possible new predictors of cardiovascular diseases: a case control study. J Nutr Metab 2012:1–5CrossRef

80.

Yoo HJ, Kim S, Park MS et al (2011) Serum adipocyte fatty acid-binding protein is associated independently with vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. J Clin Endocrinol Metab 96:E488–E492PubMedCrossRef

81.

Choi KM, Kim TN, Yoo HJ et al (2009) Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol 70:569–574CrossRef

82.

Simon I, Escote X, Vilarrasa N et al (2009) Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. Obesity 17:1124–1128PubMed

83.

Corripio R, Gonzalez-Clemente JM, Perez-Sanchez J et al (2010) Weight loss in prepubertal obese children is associated with a decrease in adipocyte fatty-acid-binding protein without changes in lipocalin-2: a 2-year longitudinal study. Eur J Endocrinol 163:887–893PubMedCrossRef

84.

Stejskal D, Karpisek M, Bronsky J (2008) Serum adipocyte-fatty acid binding protein discriminates patients with permanent and temporary body weight loss. J Clin Lab Ana 22:380–382CrossRef

85.

Wu Y-W, Kao H-L, Huang C-L et al (2012) The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 39:399–407PubMedCrossRef

86.

Xu A, Tso AW, Cheung BM et al (2007) Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 115:1537–1543PubMedCrossRef

87.

Choi KM, Yannakoulia M, Park MS et al (2011) Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr 93:19–26PubMedCrossRef

88.

Tso AW, Xu A, Sham PC et al (2007) Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 30:2667–2672PubMedCrossRef

89.

Furuhashi M, Ishimura S, Ota H et al (2011) Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One 6:e27356PubMedCrossRef

90.

Tso AWK, Lam TKY, Xu A et al (2011) Serum adipocyte fatty acid-binding protein associated with ischemic stroke and early death. Neurology 76:1968–1975PubMedCrossRef

91.

von Eynatten M, Breitling LP, Roos M et al (2012) Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 32:2327–2335CrossRef

Title: Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?
Authors: S. Kralisch
M. Fasshauer
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 1/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2737-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice

Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype

Fertility in people with childhood-onset type 1 diabetes

Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation

Association between dietary meat consumption and incident type 2 diabetes: the EPIC-InterAct study

Direct effect of GLP-1 infusion on endogenous glucose production in humans

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page